EPG Online Twitter 
EPG Online Blog 
Disease Knowledge Drug Updates
- Enbrel 25 mg powder and solvent for solution for injection
- Sustiva 50 mg, 100 mg and 200 mg Hard Capsules
- Sandostatin LAR
- Difflam Oral Rinse
- Teoptic 1% - Teoptic 2%
- Erythroped A 500 mg Tablets
- Enalapril 5mg Tablets
- Viskaldix Tablets
- Aricept Tablets
- Difflam Cream
- Alfentanil 500 micrograms/ml solution for injection
- Revlimid
- Benadryl Plus Capsules
- Diclomax Retard
- Voltarol Tablets
- Virgan
- DIXARIT (menopausal disorders)
- Rapiscan (regadenoson)
- Neurontin Capsules and Tablets
- Aprovel Film-Coated Tablets (sanofi-aventis Bristol-Myers Squibb SNC)
- Foradil
- Nystatin-Dome Suspension 100,000 I.U./ml
- Meningitec in pre-filled syringe
- Catapres Tablets 100mcg
- Kemadrin 5 mg Tablets
- SECTRAL 400mg tablets
- Sectral 100mg and 200mg
- Eucardic 25mg Tablets
- ALDOMET Tablets 250 mg
- Parvolex 200 mg/ml Concentrate for Solution for Infusion
- Mifegyne
- Pedea 5 mg/ml solution for injection
- Eucardic 12.5mg Tablets
- Qvar 100 Easi-Breathe
- Qvar 50 Easi-Breathe
- Eucardic 6.25mg Tablets
- Qvar MDI 50 micrograms
- Sonata 5 mg hard capsules
- PRO-EPANUTIN
- Xarelto 20mg film-coated tablets
Asthma
Please note- this EPG Asthma Knowledge Centre is for Doctors and other Healthcare Professionals. Enter the Asthma Knowledge Centre.
Asthma is a disorder defined by its clinical, physiological, and pathological characteristics. The main physiological feature of asthma is episodic airway obstruction characterized by expiratory airflow limitation. The dominant pathological feature is airway inflammation, sometimes associated with airway structural changes. 
Pharmacologic management of asthma aims to control symptoms, prevent exacerbations and provide the best possible pulmonary function with minimal medications, side effects and risk factors.
During exacerbations, the patient will often have wheeze and reduced lung function, either reduced peak flow or an obstructive pattern on spirometry.
Two major areas of potential improvement fof asthma. Inadequate ICS use is one of the major factors that impact the failure of long-term management.1 Also, following a general trend throughout the world, a more practical, symptom-based approach to diagnosis is warranted at the primary care level.1
There is now good evidence that the clinical manifestations of asthma—symptoms, sleep disturbances, limitations of daily activity, impairment of lung function, and use of rescue medications—can be controlled with appropriate treatment.
Enter the Asthma Knowledge Centre
What’s in the Asthma Knowledge Centre?
- Burden of Disease
- Causes of asthma
- Definition of Asthma
- Development & Progression of Asthma in adolescents and children
- Asthma Home
- Inflammation in the peripheral airways
- Pathophysiology - Asthmatic Inflammation
- Pathophysiology of asthma
- The asthmatic response
- Worldwide Prevalence
- Classification
- Diagnosis
- Education
- Levels of asthma control
- Management
- Measurement of airway responsiveness
- Measurements of Lung Function
- Peak expiratory flow measurements
- Risk Factors
- Signs & Symptoms
- Spirometry tests
- Resources -Weblinks
- Alvesco - Summary of Product Characteristics (SPC)
- Alvesco
- Clinical efficacy
- Corticosteroids
- Management using the stepwise approach
- Monitoring to maintain control
- Pharmacodynamics - Targeted deposition and activation
- Pharmacokinetics of Alvesco
- Safety and tolerability
- Treatment Options - Non-Pharmacologic
- Treatment Options - Pharmacologic
- BECODISKS
... Moderate asthma (PEF values 60-80% predicted at baseline with 20-30% variability): Patients requiring regular asthma medication and patients with unstable or worsening asthma on other prophylactic therapy or bronchodilator alone. Severe asthma (PEF values less than 60% predicted at baseline with ... - FLIXOTIDE Diskhaler
... intermittent symptomatic bronchodilator asthma medication on a regular daily basis. Moderate asthma: Patients with unstable or worsening asthma despite prophylactic therapy or bronchodilator alone. Severe asthma: Patients with severe chronic asthma and those who are dependent on systemic ... - SINGULAIR
... indicated in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short acting ?-agonists provide inadequate clinical control of asthma. In those asthmatic patients in ... - VENTODISKS
... adrenoceptors of bronchial muscle. With its fast onset of action, it is particularly suitable for the relief of acute asthma symptoms and the prevention of exercise induced asthma. Salbutamol provides short-acting (4-6 hour) bronchodilation with fast onset (within 5 minutes) in reversible airways ... - PULVINAL SALBUTAMOL
... for the relief of symptoms of asthma, bronchospasm and/or reversible airways obstruction and for the prevention of exercise-and allergen-induced asthma. Pulvinal Salbutamol is particularly suitable for the relief of symptoms in mild, moderate and severe asthma . The use of an inhaled 2-agonist must ... - BECLOFORTE
... asthma . It provides effective anti-inflammatory action in the lungs with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically. Becloforte Inhaler is indicated in the prophylactic management of severe asthma in adults. Severe asthma ...
